Research Article

Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma

Table 3

The relationship between the signature and clinical features.

idAgeGenderGradeStageTMN

MMP90.005 (0.996)0.569 (0.571)5.384 (2.875-07)−1.611 (0.110)−1.966 (0.051)−1.098 (0.319)−0.592 (0.555)
RBP7−0.7 (0.485)1.125 (0.268)2.232 (0.027)−2.055 (0.042)−1.859 (0.066)−1.316 (0.245)−1.611 (0.114)
PDGFRA−0.422 (0.674)0.778 (0.442)3.048 (0.004)−3.046 (0.003)−3.008 (0.003)−0.481 (0.647)−1.242 (0.218)
AHNAK−0.899 (0.370)1.378 (0.176)5.605 (7.957-07)−3.667 (3.488-04)−3.898 (1.461-04)0.926 (0.389)−2.267 (0.026)
OAS12.082 (0.039)−2.634 (0.010)−2.181 (0.045)2.19 (0.032)2.18 (0.032)2.913 (0.023)1.74 (0.085)
OLR10.702 (0.484)−0.098 (0.922)1.415 (0.170)−1.059 (0.292)−1.021 (0.309)2.971 (0.005)−0.393 (0.695)
RAC3−0.491 (0.624)0.868 (0.390)2.724 (0.009)−0.472 (0.638)0.142 (0.887)−1.139 (0.306)−1.763 (0.083)
SLIT2−0.968 (0.335)1.006 (0.320)3.448 (0.001)−3.546 (5.295-04)−3.545 (5.237-04)−1.724 (0.144)−1.937 (0.057)
IGF10.152 (0.879)0.776 (0.442)2.909 (0.004)−3.54 (5.794-04)−3.087 (0.003)−0.981 (0.365)−1.126 (0.264)
AGTR1−1.482 (0.141)0.54 (0.592)−0.795 (0.439)0.37 (0.712)0.427 (0.670)0.032 (0.976)0.719 (0.473)
riskScore−0.297 (0.767)2.126 (0.041)2.479 (0.019)−2.683 (0.008)−2.595 (0.010)−0.931 (0.394)−1.806 (0.075)